Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Emily Bodnar upgrades MiNK Therapeutics (NASDAQ:INKT) from Neutral to Buy and maintains the ...
MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(1.06) per share which missed the analyst consensus estimate of $...
HC Wainwright & Co. analyst Emily Bodnar downgrades MiNK Therapeutics (NASDAQ:INKT) from Buy to Neutral and maintains th...
MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural kille...
